Skip to Main content Skip to Navigation
Journal articles

High levels of HPV16-L1 antibody but not HPV16 DNA load or integration predict oropharyngeal patient outcome: The Papillophar study

Abstract : The incidence of oropharyngeal cancers (OPC) is increasing in the world. Among OPC, those induced by human papillomaviruses have a better prognosis than non-HPV-associated OPC. The objective of this study was to highlight the relevance of HPV16 load, HPV16 DNA integration and HPV16-L1 serology on progression-free survival and overall survival of OPC patients. The PAPILLOPHAR cohort consists of 362 patients with oropharyngeal squamous cell carcinomas prospectively followed up for 5 years after treatment. Tumor biopsies and sera were collected at inclusion to investigate tumor HPV DNA/RNA characteristics and HPV16 L1 serology, respectively. Twenty-seven percent of tumor biopsies were HPV DNA- and RNA-positive and HPV16 represented 93% of HPV-positive cases. Among them, neither HPV16 viral load nor HPV16 DNA integration was associated with overall survival (OS) or progression-free survival (PFS). In contrast, high anti-HPV16 L1 antibody titers were significantly associated with a better OS and PFS. This study reveals that HPV16 load and integration are not relevant prognosis biomarkers in OPC patients. Clinical Relevance: High levels of HPV16 L1 antibodies may be useful to predict OPC patient outcome following treatment. ClinicalTrials.gov Identifier: NCT00918710, May 2017.
Document type :
Journal articles
Complete list of metadata

https://hal.univ-reims.fr/hal-03603889
Contributor : valerian dormoy Connect in order to contact the contributor
Submitted on : Thursday, March 10, 2022 - 10:52:39 AM
Last modification on : Thursday, August 4, 2022 - 5:28:02 PM

Identifiers

Citation

Jean-Luc Prétet, Véronique Dalstein, Antoine Touzé, Agnès Beby-Defaux, Patrick Soussan, et al.. High levels of HPV16-L1 antibody but not HPV16 DNA load or integration predict oropharyngeal patient outcome: The Papillophar study. Clinical and Experimental Medicine, Springer Verlag, 2022, ⟨10.1007/s10238-022-00796-2⟩. ⟨hal-03603889⟩

Share

Metrics

Record views

22